{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:20:28Z","timestamp":1787775628957,"version":"build-2784847793"},"reference-count":7,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1]]},"abstract":"\n AIM:<\/jats:title>\n The current work establishes an easy, reliable technique for the estimation of serum Olanzapine concentration which correlates it clinically.<\/jats:p>\n <\/jats:sec>\n \n SUBJECTS AND METHODS:<\/jats:title>\n The work was agreed in 61 schizophrenic patients who were on olanzapine. Serum drug amount was estimated by normal-phase high-performance liquid chromatography and brief psychiatry rating scale was used to determine disease progression.<\/jats:p>\n <\/jats:sec>\n \n RESULTS:<\/jats:title>\n Samples provided 61 patients, 40 were under sub-therapeutic range, 18 were under therapeutic range and 3 were above the therapeutic range.<\/jats:p>\n <\/jats:sec>\n \n CONCLUSION:<\/jats:title>\n Therapeutic drug monitoring must be a part of clinical practice in psychiatric hospitals for optimizing the dose of an individual patient along with the correlation of serum concentration with the clinical assessment scales.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/ijp.ijp_114_20","type":"journal-article","created":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T09:02:45Z","timestamp":1619600565000},"page":"2-5","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Therapeutic drug monitoring of olanzapine"],"prefix":"10.4103","volume":"53","author":[{"given":"Srinivas Pramod","family":"Junutula","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai Kiran","family":"Dubasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai Geethika Reddy","family":"Padide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gireesh Kumar","family":"Miryala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manasa Soumya","family":"Koppolu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharvana Bhava Bandaru","family":"Sheshagiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkateshwarlu","family":"Eggadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-2-20240903","doi-asserted-by":"crossref","first-page":"442","DOI":"10.2165\/00003088-199529060-00005","article-title":"Therapeutic drug monitoring for the treatment of psychiatric disorders. Clinical use and cost effectiveness","volume":"29","author":"Eilers","year":"1995","journal-title":"Clin Pharmacokinet"},{"key":"R3-2-20240903","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0378-4347(95)00061-M","article-title":"Analysis of olanzapine in human plasma utilizing reversed-phase high-performance liquid chromatography with electrochemical detection","volume":"668","author":"Catlow","year":"1995","journal-title":"J Chromatogr B"},{"key":"R4-2-20240903","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/00007691-199706000-00011","article-title":"Plasma level monitoring of olanzapine in patients with schizophrenia: Determination by high-performance liquid chromatography with electrochemical detection","volume":"19","author":"Aravagiri","year":"1997","journal-title":"Ther Drug Monit"},{"key":"R5-2-20240903","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0378-4347(98)00205-9","article-title":"Determination of olanzapine in serum by high-performance liquid chromatography using ultraviolet detection considering the easy oxidability of the compound and the presence of other psychotropic drugs","volume":"714","author":"Olesen","year":"1998","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"R6-2-20240903","first-page":"191","article-title":"Determination of olanzapine in plasma by high-performance liquid chromatography using ultraviolet absorbance detection","volume":"773","author":"Dusci","year":"2002","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"R7-2-20240903","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1177\/0269881115586285","article-title":"Olanzapine and risperidone plasma concentration therapeutic drug monitoring: A feasibility study","volume":"29","author":"Law","year":"2015","journal-title":"J Psychopharmacol"},{"key":"R8-2-20240903","first-page":"1","article-title":"Isocratic high-performance liquid chromatographic assay of olanzapine: Method development and validation","volume":"2014","author":"Basavaiah","year":"2014","journal-title":"Hindawi"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.IJP_114_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:36:45Z","timestamp":1787773005000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.IJP_114_20"}},"subtitle":["Easy and reliable method for clinical correlation"],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":7,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/ijp.ijp_114_20","relation":{},"ISSN":["0253-7613"],"issn-type":[{"value":"0253-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]}}}